약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
Table. 3. Factors influencing the prescription of triple antiemetic therapy
Crude OR p-value Adjusted OR p-value
Sex
male 1.00[Reference] 1.00[Reference]
female 1.058[0.670-1.671, 95% CI] 0.8073 0.981[0.575-1.673, 95% CI] 0.9437
Age
<65 1.00[Reference] 1.00[Reference]
≥65 1.277[0.804-2.028, 95% CI] 0.3001 1.143[0.667-1.958, 95% CI] 0.6276
Insurance type
Health insurance 1.00[Reference] 1.00[Reference]
Others 0.760[0.230-2.513, 95% CI] 0.7743 0.760[0.230-2.513, 95% CI] 0.6531
Type of healthcare facility
Tertiary general hospital 1.00[Reference] 1.00[Reference]
Others 1.193[0.703-2.023, 95% CI] 0.5133 0.855[0.453-1.615, 95% CI] 0.6300
Region
Seoul 1.00[Reference] 1.00[Reference]
Metropolitan 0.703[0.383-1.291, 95% CI] 0.1603 0.508[0.246-1.049, 95% CI] 0.0933
Non-Metropolitan 1.130[0.670-1.905, 95% CI] 0.2526 0.842[0.450-1.577, 95% CI] 0.5954
Chemotherapy
CHOP-based therapy 1.00[Reference] 1.00[Reference]
ABVD 0.082[0.020-0.338, 95% CI] 0.0005 0.086[0.019-0.388, 95% CI] 0.0017
Daunorubicin+cytarabine-based therapy 0.041[0.004-0.431, 95% CI] 0.0078 0.028[0.003-0.316, 95% CI] 0.005
Others 0.107[0.054-0.213, 95% CI] <.0001 0.086[0.041-0.180, 95% CI] <.0001
NCI comorbidity index
0 1.00[Reference] 1.00[Reference]
1 0.843[0.478-1.485, 95% CI] 0.2000 0.575[0.294-1.127, 95% CI] 0.1608
2 0.590[0.206-1.687, 95% CI] 0.0906 0.430[0.122-1.518, 95% CI] 0.1338
≥3 4.717[1.046-21.263, 95% CI] 0.0224 3.040[0.607-15.226, 95% CI] 0.0604
Yakhak Hoeji 2024;68:311-9 https://doi.org/10.17480/psk.2024.68.5.311
© 2024 Yakhak Hoeji